CYP2C19*2 - The Clopidogrel Gene
CYP2C19 is a drug-metabolizing enzyme with enormous clinical significance,
particularly for the antiplatelet drug clopidogrel (Plavix). The *2 allele| rs4244285
is the most common loss-of-function variant, rendering the enzyme
completely non-functional. This variant carries an FDA black-box warning | Clopidogrel (Plavix) prescribing label, FDA on the
clopidogrel label - one of the clearest examples of pharmacogenomics directly
affecting prescribing decisions.
The Mechanism
The CYP2C19*2 variant is a synonymous change (G>A at position 681 in exon 5)
that creates an aberrant splice site| Despite being synonymous at the protein level, this variant disrupts normal mRNA splicing,
producing a truncated, non-functional protein.
Although the nucleotide change itself does not alter the encoded amino acid (Pro227=),
it introduces a cryptic splice site that shifts the reading frame, leading to a
premature stop codon. Homozygous carriers (AA) have no CYP2C19 activity and are
classified as poor metabolizers.
The Clopidogrel Crisis
Clopidogrel is a prodrug| A prodrug is inactive until the body converts it to its active form that REQUIRES CYP2C19 to be converted to its active
antiplatelet metabolite. Poor metabolizers who take clopidogrel after coronary stent
placement have significantly higher rates of stent thrombosis, heart attack, and
cardiovascular death. A landmark study by Mega et al. | Mega JL et al. Reduced-function CYP2C19 genotype and risk of cardiovascular events. JAMA, 2010
confirmed this association across multiple trials, leading to the FDA black-box warning | Clopidogrel (Plavix) prescribing label, FDA.
Beyond Clopidogrel
CYP2C19 also metabolizes proton pump inhibitors (PPIs like omeprazole and
pantoprazole), certain antidepressants (citalopram, escitalopram, sertraline),
and antifungal agents (voriconazole). For PPIs, poor metabolizers actually benefit
because the drug stays active longer, providing better acid suppression. For
antidepressants, poor metabolizers may need dose reductions.
What You Should Do
If you are a poor metabolizer (AA), the clopidogrel information is potentially
life-saving. If you ever need antiplatelet therapy (after a stent, stroke, or
peripheral vascular disease), you MUST use an alternative like prasugrel or
ticagrelor. Share this information with your cardiologist and keep it in your
medical records.
All Genotypes
Normal CYP2C19 activity at *2 position
No loss-of-function variant at this position. About 72% of Europeans share this genotype, though the frequency varies by ancestry -- it is less common in East Asian and South Asian populations where the *2 allele is more prevalent.
Intermediate CYP2C19 metabolizer
You carry one no-function CYP2C19*2 allele, giving you intermediate metabolizer status. This affects medications like clopidogrel (Plavix), PPIs (omeprazole, pantoprazole), and some antidepressants. For clopidogrel, you may have reduced antiplatelet effect.
Poor CYP2C19 metabolizer - clopidogrel ineffective
You are a CYP2C19 poor metabolizer. About 3% of Europeans share this genotype, with higher frequencies in East Asian populations. This has critical implications: CLOPIDOGREL (PLAVIX) WILL NOT WORK FOR YOU. This antiplatelet medication needs CYP2C19 to convert it to its active form. If you need antiplatelet therapy after stent placement or for stroke prevention, you need an alternative. PPIs like omeprazole will actually work BETTER for you since they won't be broken down as quickly.